PDF   Print   View All
May 17, 2004
Expanded Application includes Unique Oral Delivery Mechanism

Philadelphia, PA, Monday, May 17, 2004: Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it filed an expanded U.S. patent application covering the use of its lead compounds, Alferon N Injection®, Ampligen® and Alferon LDO® for the potential treatment and prevention of severe acute respiratory syndrome (SARS) and dreaded emerging viruses.

Independent studies, including those sponsored by various governmental agencies, have identified Alferon N, a natural source, multispecies alpha interferon product, and Ampligen®, an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral, as first candidates for potentially treating SARS. The patent application that has been filed provides procedures for treating the effects of coronavirus-induced conditions by the administration of Alferon N Injection® or Ampligen®, as well as a method of mitigating the effects of or conferring resistance to SARS co, prior to exposure or shortly after exposure but prior to symptoms by the administration of Alferon LDO@.

Hemispherx has a large knowledge and expertise in the procedures of filing patents and has built up potentially one of the largest patent portfolios in the biotech industry. Due to the acquisition of the Alferon technology, the Company has further enlarged its world wide patent estate with respect to Alferon N Injection®, including several process patents related to the manufacturing of natural alpha interferon.

About Ampligen®
Ampligen® is an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral. Based on in vitro studies, Ampligen® is believed to modulate the immune system as well as inhibit viruses directly. The experimental product is currently in a Phase III clinical trial for the potential treatment of Chronic Fatigue Syndrome (CFS) and in two Phase IIb clinical trials for the potential treatment of HIV/AIDS. SARS, which is believed to be a coronavirus and the HIV virus, both belong to the group of ribose nucleic acid (RNA) viruses which frequently change and mutate. At the 16th and 17th International Virology Conferences, the Company announced the promising data on various fronts, including a NIH sponsored study on SARS finding Ampligen® having unusually high and consistent antiviral activity against human coronavirus. The study found Ampligen® among the most active drug candidates, compared to approximately 70 others studied in vitro.

About Alferon N Injection®
Alferon N (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of a specific indication of STD (refractory condylomata acuminata) and is also approved for sale in certain other countries, including Hong Kong (Peoples Republic of China) and Singapore. On April 19, 2004 the Company announced the results of an independent study, conducted by the Genome Institute of Singapore, suggesting that Alferon N Injection, tested among 19 clinically approved compounds from several major antiviral pharmacologic classes, exhibits the most potent antiviral activity in an in-vitro model of SARS-CoV infection.

About Alferon LDO®
Alferon LDO, administered orally, is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster an immune response through the entire body orally. Oral administration of Alferon N, with its affordability, low toxicity, no production of antibodies, and broad range of potential bio activity, could be a breakthrough treatment for viral diseases.
About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens™. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N®) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6369

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will ever be specifically approved commercially for these other treatment indication.